GlassScriptPhysician profile
Jack R Hudkins
NPI 1306064092
$3,726.35
in general payments reported to CMS, 2019-2025
49 companies · $922 in 2025
The $922 reported for 2025 was more than what a typical Surgery provider received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $449 · 2020: $261 · 2021: $532 · 2022: $537 · 2023: $476 · 2024: $548 · 2025: $922.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,576 · Long Term Medical Supply Or Device Loan: $370.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,575.94 |
| Long Term Medical Supply Or Device Loan | $370.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $389.86 | 2022-2025 | Nexpowder, Maxtack |
| Pentax of America, INC. | $370.36 | 2025 | Pentax Medical, Sony |
| Teva Pharmaceuticals USA, INC. | $254.27 | 2019-2025 | Austedo Xr, Austedo Xr, Uzedy |
| Abbvie INC. | $254.21 | 2020-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $244.30 | 2019-2025 | Jardiance, Synjardy, Tradjenta |
| Novo Nordisk INC | $193.02 | 2019-2024 | Wegovy |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $162.92 | 2019-2025 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $162.05 | 2023-2025 | Caplyta |
| Amgen INC. | $130.20 | 2019-2024 | Otezla, Repatha |
| Davol INC. | $111.72 | 2023 | Phasix Mesh |
| Takeda Pharmaceuticals U.S.A., INC. | $108.82 | 2019-2021 | |
| Genzyme Corporation | $82.53 | 2025 | |
| Dexcom, INC. | $77.43 | 2022-2025 | Dexcom G6 Transmitter |
| Portola Pharmaceuticals, LLC | $71.90 | 2019 | |
| Merck Sharp & Dohme LLC | $63.49 | 2020-2021 |
Show all 49 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jack Hudkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.